BI 224436 is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as a targeted inhibitor, specifically designed to interfere with certain cellular pathways that are crucial for the survival and proliferation of cancer cells. By targeting these pathways, it aims to induce apoptosis or inhibit tumor growth, making it a promising candidate for the treatment of various types of cancers. Preclinical studies have shown its efficacy in reducing tumor size and improving survival rates in animal models. Researchers are also exploring its potential in combination therapies to enhance the overall effectiveness of cancer treatments. Further clinical trials are necessary to determine its safety, efficacy, and optimal dosing in humans.